**Ex-Seagen CEO to return to Bothell to lead newly relocated biotech firm**

Clay Siegall, the former CEO of Seagen, is set to lead Immunome as it relocates its headquarters to Bothell, Washington. This appointment follows Siegall's resignation from Seagen amid serious domestic abuse allegations, which authorities did not pursue due to inconsistent witness statements. His recent role as president and CEO of Morphimmune, which has now merged with Immunome, marks a significant return to leadership in the biotech sector. The merger aims to capitalize on Siegall's extensive experience in cancer therapy development, focusing on innovative oncology solutions. Siegall's previous tenure at Seagen saw the company become a pioneering force in antibody-drug conjugates, achieving several FDA approvals and substantial yearly revenue.

The decision to move Immunome to the Alloy Innovation Center in Bothell is expected to enhance the company's research capabilities and local impact. Siegall expressed enthusiasm about the merger, highlighting the potential to alleviate suffering caused by cancer through advanced therapies. This development is pivotal for both Siegall and the growing biotech community in the Seattle area.